RELAXIN H2 (HUMAN)
| 中文名称 | RELAXIN H2 (HUMAN) |
|---|---|
| 中文同义词 | |
| 英文名称 | Relaxin H2 (human) |
| 英文同义词 | Relaxin H2 (human);(Pyr-Leu-Tyr-Ser-Ala-Leu-Ala-Asn-Lys-Cys-Cys-His-Val-Gly-Cys-Thr-Lys-Arg-Ser-Leu-Ala-Arg-Phe-Cys-OH)A(H-Asp-Ser-Trp-Met-Glu-Glu-Val-Ile-Lys-Leu-Cys-Gly-Arg-Glu-Leu-Val-Arg-Ala-Gln-Ile-Ala-Ile-Cys-Gly-Met-Ser-Thr-Trp-Ser-OH)B;(Pyr-Leu-Tyr-Ser-Ala-Leu-Ala-Asn-Lys-Cys-Cys-His-Val-Gly-Cys-Thr-Lys-Arg-Ser-Leu-Ala-Arg-Phe-Cys-OH)A(H-Asp-Ser-Trp-Met-Glu-Glu-Val-IleLys-Leu-Cys-Gly-Arg-Glu-Leu-Val-Arg-Ala-Gln-Ile-Ala-Ile-Cys-Gly-Met-Ser-Thr-Trp-Ser-OH)B(Cys10A&Cys15ABridge,Cys11A&Cys1;PubChem ID: 71300755;Relaxin H2 (human) trifluoroacetate salt;(Pyr-Leu-Tyr-Ser-Ala-Leu-Ala-Asn-Lys-Cys-Cys-His-Val-Gly-Cys-Thr-Lys-Arg-Ser-Leu-Ala-Arg-Phe-Cys-OH)A(H-Asp-Ser-Trp-Met-Glu-Glu-Val-IleLys-Leu-Cys-Gly-Arg-Glu-Leu-Val-Arg-Ala-Gln-Ile-Ala-Ile-Cys-Gly-Met-Ser-Thr-Trp-Ser-OH)B(Cys10A&Cys15ABridge,Cys11A&Cys11BBridge,Cys24A&Cys23BBridge)(Relax in H2 Human);Human relaxin II |
| CAS号 | 99489-94-8 |
| 分子式 | C256H408N74O74S8 |
| 分子量 | 5962.95012 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 99489-94-8.mol |
| 结构式 |  |
RELAXIN H2 (HUMAN) 性质
| 储存条件 | Store at -20°C |
|---|---|
| 溶解度 | 溶于二甲基亚砜 |
Serelaxin (RLX-030) 是一种靶向 RLN 受体 的重组人松弛素，是一种具有抗纤维化活性的血管活性肽激素。
Serelaxin (0.5 mg/kg per day, subcutaneous administration) produces 20 to 40 ng/mL of circulating hormone, which successfully prevents and reduces fibrosis progression in various experimental models of injury. The doses do not exhibit significant toxicity.
Serelaxin restores endothelial function by increasing nitric oxide (NO)-mediated relaxation but not endothelium-derived hyperpolarisation (EDH).
| Animal Model: | Six- to 8-week-old male mice (on a 129sv or 129sv×C57B6J background, which were equally sensitive to tissue injury and fibrosis). |
| Dosage: | 0.5 mg/kg. |
| Administration: | Subcutaneous administration per day for 7 days. |
| Result: | Produced 20 to 40 ng/mL of circulating hormone. |